Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs GeneDx Holdings Corp — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.18, while GeneDx Holdings Corp trades at $60.76 (market cap $1.80B). The key difference: JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| JPIN | WGS | |
|---|---|---|
52-Week High | $76.96 | $167.51 |
52-Week Low | $63.14 | $34.51 |
Market Cap | — | $1.80B |
Sector | — | Technology |
Enterprise Value | — | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN trades at $73.11, down 0.5% on the day, with technical indicators showing a neutral to bearish bias. The ETF lacks disclosed fundamental ratios, and a dividend of $0.91 is scheduled for June 2026. Recent coverage highlights its smart beta approach to international equity exposure since its 2014 launch.
The outlook remains neutral amid mixed technical signals and absent fundamental data. Risks include reliance on international markets and valuation opacity. Investor sentiment is cautious without clear earnings metrics or analyst consensus, requiring due diligence on underlying holdings and strategy.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
